Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data

被引：0
|
作者：
Holland C Detke
Fangyi Zhao
Michael M Witte
机构：
[1] Eli Lilly and Company,
[2] Lilly USA,undefined
[3] LLC,undefined
来源：
BMC Psychiatry | / 12卷
关键词：
Olanzapine; Long-acting injection; Pamoate; Haloperidol; Effect size; Onset; Pharmacokinetics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Efficacy of olanzapine long-acting injection in patients with acutely exacerbated schizophrenia: an insight from effect size comparison with historical oral data
    Detke, Holland C.
    Zhao, Fangyi
    Witte, Michael M.
    BMC PSYCHIATRY, 2012, 12
  • [2] Effects of olanzapine long-acting injection on levels of functioning among acutely ill patients with schizophrenia
    Witte, Michael M.
    Case, Michael G.
    Schuh, Kory J.
    Ascher-Svanum, Haya
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (03) : 315 - 323
  • [3] Efficacy and safety of olanzapine long-acting injection for maintenance treatment of schizophrenia
    Detke, H.
    McDonnell, D.
    Kane, J.
    Naber, D.
    Sethuraman, G.
    Lin, D.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2008, 18 : S393 - S394
  • [4] Comparison of metabolic changes in patients with schizophrenia during randomized treatment with intramuscular olanzapine long-acting injection versus oral olanzapine
    McDonnell, David P.
    Kryzhanovskaya, Ludmila A.
    Zhao, Fangyi
    Detke, Holland C.
    Feldman, Peter D.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2011, 26 (06) : 422 - 433
  • [5] Assessing the infrequent oral supplementation of olanzapine long-acting injection in the treatment of schizophrenia
    Ascher-Svanum, H.
    Peng, X.
    Montgomery, W.
    Faries, D. E.
    Lawson, A. H.
    Witte, M. M.
    Novick, D.
    Jemiai, N.
    Perrin, E.
    McDonnell, D. P.
    EUROPEAN PSYCHIATRY, 2011, 26 (05) : 313 - 319
  • [6] Comparison of metabolic parameters during treatment for schizophrenia with olanzapine intramuscular long-acting injection versus olanzapine oral formulation
    Gulliver, A.
    McDonnell, D. P.
    Kryzhanovskaya, L. A.
    Zhao, F.
    Detke, H. C.
    Feldman, P. D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 152
  • [7] Olanzapine long-acting injection: Pharmacokinetic and dose correspondence data relative to oral olanzapine
    Gulliver, A.
    Detke, H. C.
    McDonnell, D. P.
    Bergstrom, R. F.
    Lin, D.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2008, 11 : 152 - 153
  • [8] Comparison of long-acting antipsychotic injection and oral antipsychotics in schizophrenia
    Olivares, Jose M.
    Pinal, Beatriz
    Cinos, Carmen
    NEUROPSYCHIATRY, 2011, 1 (03) : 275 - 289
  • [9] Safety and efficacy of olanzapine long-acting injection for up to 6 years in patients with schizophrenia or schizoaffective disorder
    McDonnell, D. P.
    Detke, H. C.
    Choukour, M.
    Landry, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2012, 22 : S319 - S320
  • [10] Profile of olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia
    Di Lorenzo, Rosaria
    Brogli, Alice
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2010, 6 : 573 - 581
12345